Aditya Bardia, MD, MPH

Articles

Optimizing Management of HR+/HER2- BC: Future Directions in Care

August 15th 2022

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

Considerations for Use of ADCs in HER2-Low Breast Cancer

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

August 1st 2022

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

August 1st 2022

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

Dr. Bardia on the Need for Oral SERDs in ESR1-Mutant ER+ Breast Cancer

July 29th 2022

Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.

HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

July 25th 2022

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

July 25th 2022

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

Frontline Combination Strategies in HR+/HER2- BC

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

July 11th 2022

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v

HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

July 11th 2022

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

Dr. Bardia on the Rationale of Utilizing Endocrine Therapy in ER+ Breast Cancer

March 14th 2022

Aditya Bardia, MD, MPH, discusses the use of endocrine therapy in estrogen receptor–positive breast cancer.

Practical Advice on the Use of ctDNA Testing in Breast Cancer

February 16th 2022

Closing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.

Other Clinical Studies on ctDNA Use in Breast Cancer

February 16th 2022

Shared insight on how clinical trial data behind circulating tumor DNA in breast cancer may affect future treatment strategies.

SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

February 14th 2022

Patrick Neven MD, PhD; Sara A. Hurvitz, MD; Kevin Kalinsky, MD, MS; and Aditya Bardia, MD, MPH, share insight on updates in key clinical trials and novel therapies in breast cancer presented at SABCS 2021.

ctDNA in Breast Cancer: Cancer Detection Vs Therapy Selection

February 9th 2022

A brief synopsis on the use of circulating tumor DNA for cancer detection versus treatment selection in breast cancer management.

Role of ctDNA in the Adjuvant Setting of Breast Cancer

February 9th 2022

Aditya Bardia, MD, MPH, and Barry Rosen, MD, discuss the role of circulating tumor DNA in the adjuvant setting of breast cancer.